Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety Study of BAT1706 vs Avastin in Healthy Subjects
NCT03030430Phase 1Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Mar 2016
- Primary completion
- May 2017
- Modality
- RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of avacincaptad pegol in non-small cell lung cancer (NSCLC), metastatic colorectal cancer (mCRC), glioblastoma (GBM) and 3 more (3 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoint: Area Under the Curve from time zero to infinity at 4 months. Started Mar 2016; status: completed.
02
Drugs
avacincaptad pegol
03
Conditions
non-small cell lung cancer (NSCLC)metastatic colorectal cancer (mCRC)glioblastoma (GBM)renal cell carcinoma (RCC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03030430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03030430.